GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...